QTTBQ32 Bio Inc.Small cap · $190.1M · FY ending 2025-12-31
$11.21-10.96% · 2026-07-10 · EOD
65/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality72
margins & F-ScoreValue38
P/E 4.6 · 77% of 12-mo rangeMomentum82
golden · price above 200-daySmart Money67
buying · 0 funds · 2P/3S insidersBullish stackGolden crossAbove 200-day
vs S&P 500+227.2%
6-mo excess Trailing performance1M -5.7%
3M +127.8%
6M +236.6%
YTD +225.9%
1Y +642.4%
P/E vs its last 12 months (our price history): 0.7 low → 5.8 high
Current price sits at the 77th percentile of that window — near the top (richer). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Piotroski F4/9
fundamental strength Altman ZSafe
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 0%. Annual figures from SEC XBRL.
Net buying2P / 3S insiders · 0 funds hold · 0 Congress buys
Recent insidersORBIMED ADVISORS LLC · DirectorBUY$15.0M
Xu Diyong · DirectorBUY$15.0M
Violette Shelia M. · Chief Scientific OfficerSELL$12,708
Morrison Jodie Pope · CEOSELL$44,675
Chealth · 56/100
May need capitalGoing-concern flagGoing-concern warning — auditor flagged substantial doubt
- ●Going-concern warning Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.